Genezen and the Raiden Science Foundation Announce Partnership for AAV9 Gene Replacement Therapy for UBA5 Clinical Trial

PartnershipAAV9 Gene Replacement TherapyPositive

AI Analysis

Summary

Genezen and the Raiden Science Foundation announced a manufacturing partnership for an AAV9 gene replacement therapy targeting UBA5 deficiency clinical trial. The collaboration aims to support the development and manufacturing of the rare disease gene therapy program.

Clinical Trial Data

Importance:5/10

Sentiment:

0.50

gene therapyAAV9rare diseasemanufacturing partnershipUBA5CDMO

Read the original article

Published by PR Newswire Biotech on August 3, 2026 12:17 PM

Read Original